In the past decade, tremendous progress has been made in the field of immunotherapy, especially in the field of T cell therapy. This method uses engineered T cells with artificial chimeric antigen receptors (CAR) as an example, which can recognize specific proteins expressed on the surface of tumor cells, resulting in rapid activation and killing of tumor cells. Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.
To solve the problem of the scope and selectivity of CAR-T, researchers are turning to a method of engineering T cells based on T cell receptors (TCR-T). The ability of TCR to selectively recognize target cells comes from its unique ability to recognize cell surface "antigens". These antigens can be used as selective identifiers for malignant cells, and more and more tumor-related antigens are being identified, enabling the engineering of a potent and selective TCR-T directed against cancer.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR/TCR technology. With state-of-art TCR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of TCR-T early development services, including TCR engineered T cell biomarker identification and selection, design, construction, and analysis. Moreover, our one-stop TCR development services also provide you the preclinical test.
Our one-stop TCR-T therapy development services include but not limited to:
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE